Abstract
BackgroundIn RA-BEGIN (NCT01711359), baricitinib (bari), an oral Janus Kinase (JAK)1/JAK2 inhibitor, improved signs and symptoms of moderately to severely active RA in patients (pts) who had received no or limited...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have